<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756456</url>
  </required_header>
  <id_info>
    <org_study_id>NGF0212</org_study_id>
    <secondary_id>2012-002527-15</secondary_id>
    <nct_id>NCT01756456</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.</brief_title>
  <acronym>REPARO</acronym>
  <official_title>An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of Recombinant Human Nerve Growth Factor in Patients With Stage 2 and 3 of NK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at assessing the safety and the efficacy of two dose regimens of
      recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for
      inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer)
      neurotrophic keratitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the safety and the efficacy of two dose
      regimens (10 µg/ml or 20 µg/ml 6 times a day) of recombinant human nerve growth factor
      (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2
      (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis (NK) as measured
      by the Reading Center evaluating the clinical pictures of corneal fluorescein staining.

      Secondary objectives of the study are to assess the duration of complete healing, improvement
      in visual acuity and improvement in corneal sensitivity following treatment with rhNGF eye
      drops solution

      This is a combined phase I/II study. The phase I and II segments of the study will be
      conducted as an 8 week, randomized, double-masked, vehicle controlled, parallel group study
      (referred to as the controlled treatment period) followed by a 48 or 56 week follow-up period
      The design of the phase I and phase II segments of the study are identical with the exception
      that in the phase I segment of the study the randomization scheme is different and patients
      will be followed with additional safety assessments and blood samples for PK
      (pharmacokinetic) profiling In the ascending dose Phase I segment of the study two doses of
      rhNGF 10 and 20 µg/ml will be evaluated in a sequential manner
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</measure>
    <time_frame>at 4 weeks of treatment</time_frame>
    <description>Complete healing of the PED or corneal ulcer was determined by corneal fluorescein staining at 4 weeks as defined by the reading center evaluating the clinical pictures.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm at the Week 4 visit.
The primary efficacy variable was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</measure>
    <time_frame>at 4 weeks of study treatment.</time_frame>
    <description>Complete healing of the PED or corneal ulcer at 4 weeks as defined by the Investigator. The complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer, being less than 0.5 mm at the Week 4 visit.
This secondary outcome was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</measure>
    <time_frame>at 6 and 8 weeks after start of the treatment</time_frame>
    <description>Complete healing of the PED or corneal ulcer at 6 and 8 weeks measured by both the central reading center and Investigator.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm.
This outcome was analyzed after 6 and 8 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing Complete Corneal Clearing</measure>
    <time_frame>at 4, 6 and 8 weeks after start of the treatment</time_frame>
    <description>Complete corneal clearing (grade 0 on the modified Oxford scale) at 4, 6 and 8 weeks.
A patient was considered to have achieved complete corneal clearing if he/she had a Modified Oxford Scale recorded as Grade 0.
The scale has the following grades: 0-1-2-3-4-5, where 5 represents the worst outcome value and 0 the best outcome value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>At screening and at week 8</time_frame>
    <description>Mean changes in Best-Corrected Distance Visual Acuity (BCDVA) from baseline to Week 8 are calculated as Least Square means. BCDVA consists of letters read at 4 meters only. Patients are scored by how many letters could be correctly identified. Therefore the higher the number of letters, the higher the visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients That Achieve an Improvement in Corneal Sensitivity</measure>
    <time_frame>at 4, 6 and 8 weeks.</time_frame>
    <description>Percentage of patients that achieve an improvement in corneal sensitivity as measured by the Cochet-Bonnet aesthesiometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing Deterioration in Stage 2 or 3 NK</measure>
    <time_frame>from baseline to Week 4, 6, and 8.</time_frame>
    <description>Percentage of patients experiencing deterioration (increase in lesion size ≥ 1mm, decrease in BCDVA by &gt;5 ETDRS letters, progression in lesion depth to corneal melting or perforation, onset of infection) in stage 2 or 3 NK from baseline to Week 4, 6, and 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Healing of the PED or Corneal Ulcer by Week 8/16 That Remain Healed at Weeks 20/28, 32/40, 44/52, 56/64</measure>
    <time_frame>at week 20/28, 32/40, 44/52, and 56/64</time_frame>
    <description>Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 that remain healed (ie, no recurrence of the PED and/or corneal ulcer) at Weeks 20/28, 32/40, 44/52, 56/64</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing a Different Level of Efficacy at 4 and 8 Weeks</measure>
    <time_frame>at week 4 and 8</time_frame>
    <description>Global evaluation of efficacy as assessed by the Investigator at 4 and 8 weeks. The different level of efficacy were: very good; good; moderate; poor; non-evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Analogue Scale (VAS) for Ocular Tolerability</measure>
    <time_frame>at baseline and at weeks 8 and 20</time_frame>
    <description>Ocular tolerability was recorded by the patient on a VAS scale from 0 to 100 mm, where a higher VAS score indicates worse ocular symptoms (0 means no symptoms and 100 means the worst possible discomfort). The overall VAS score for ocular tolerability was calculated as the mean of the individual VAS scores for the 7 different symptoms (foreign body sensation, burning/stinging, itching, ocular pain, sticky feeling, blurred vision and photophobia).
Results are below reported as per symptoms at week 8 (for treatment period) and week 20 (for Follow Up period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>at baseline and at period 1 (8 weeks) and 2 (Follow Up period of 12 weeks, until week 20)</time_frame>
    <description>Best-Corrected Distance Visual Acuity (BCDVA) by means of the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart at 4 meters (13 feet). Data reported refers to week n° 8 (treatment group) and n°12/20 (FU group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, period 1 (8 weeks) and 2 (Follow Up period of 12 weeks, until week 20).</time_frame>
    <description>IOP was measured using a Goldmann applanation tonometer, a handheld applanation tonometer [eg, Tonopen], or other tonometer, after the instillation of a topical anesthetic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Eye Structures by Dilated Fundus Ophthalmoscopy</measure>
    <time_frame>At week 8 (Phase 1 and Phase 2)</time_frame>
    <description>Dilated fundus ophthalmoscopy was performed to assess the vitreous, retina, macula, choroid and optic nerve head after dilation of the pupil.
Percentage of patients is summarized for each eye structure by treatment and visit for the controlled treatment period for Phase I and Phase II separately.
The assessment time points were Baseline, weeks 2, 4 and 8 for Phase 1; Baseline and week 8 for Phase 2; and weeks 12 and 56 for follow up.
Only results for eye structure at week 8 are reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Patients That Achieved a ≥15 Letter Gain in BCDVA</measure>
    <time_frame>at 4, 6 and 8 weeks</time_frame>
    <description>Percentage of patients that achieved a ≥15 letter gain in best corrected distance visual acuity (BCDVA) at 4, 6, and 8 weeks</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <condition>Keratitis</condition>
  <condition>Corneal Ulcer</condition>
  <arm_group>
    <arm_group_label>1_rhNGF10_Phase 1_treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2_rhNGF20_Phase 1_treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3_vehicle group_Phase 1_treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4_rhNGF10_Phase 2_treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5_rhNGF20_Phase 2_treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6_vehicle group_Phase 2_treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 10 μg/ml</intervention_name>
    <description>rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
    <arm_group_label>1_rhNGF10_Phase 1_treatment</arm_group_label>
    <arm_group_label>4_rhNGF10_Phase 2_treatment</arm_group_label>
    <other_name>recombinant human nerve growth factor 10 µg/ml solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 20 μg/ml</intervention_name>
    <description>one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
    <arm_group_label>2_rhNGF20_Phase 1_treatment</arm_group_label>
    <arm_group_label>5_rhNGF20_Phase 2_treatment</arm_group_label>
    <other_name>recombinant human nerve growth factor 20 µg/ml solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vehicle</intervention_name>
    <description>ophthalmic solution of the same composition as the test product without rhNGF</description>
    <arm_group_label>3_vehicle group_Phase 1_treatment</arm_group_label>
    <arm_group_label>6_vehicle group_Phase 2_treatment</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older.

          2. Patients with stage 2 (persistent epithelial defect, PED) or stage 3 (corneal ulcer)
             neurotrophic keratitis involving only one eye. . Patients with Controlateral eye
             affected with stage 1 NK can be enrolled.

          3. PED or corneal ulceration of at least 2 weeks duration refractory to one or more
             conventional non-surgical treatments for neurotrophic keratitis (e.g.,
             preservative-free artificial tears, gels or ointments; discontinuation of preserved
             topical drops and medications that can decrease corneal sensitivity; therapeutic
             contact lenses).

          4. Evidence of decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet
             aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of
             the defect in at least one corneal quadrant.

          5. Best corrected distance visual acuity (BCDVA) score ≤ 75 ETDRS letters, (≥ 0.2 LogMAR,
             ≤ 20/32 Snellen or ≤ 0.625 decimal fraction) in the affected eye.

          6. No objective clinical evidence of improvement in the PED or corneal ulceration within
             the 2 weeks prior to study enrolment.

          7. Only patients who satisfy all Informed Consent requirements may be included in the
             study. The patient and/or his/her legal representative must read, sign and date the
             Informed Consent document before any study-related procedures are performed. The
             Informed Consent form signed by patients and/or legal representative must have been
             approved by the IEC/IRB for the current study.

          8. Patients must have the ability and willingness to comply with study procedures.

          9. Patients must be eligible for the National Health Insurance (where applicable).

        Exclusion Criteria:

          1. Patients with stage 2 or 3 NK affecting both eyes.

          2. Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular
             inflammation not related to NK in the affected eye.

          3. Any other ocular disease requiring topical ocular treatment in the affected eye during
             the course of the study treatment period. No topical treatments other than the study
             medications provided by the study sponsor or allowed by the study protocol can be
             administered in the affected eye during the course of the study treatment periods.

          4. Patients with severe vision loss in the affected eye with no potential for visual
             improvement in the opinion of the investigator as a result of the study treatment.

          5. Schirmer test without anesthesia ≤3 mm/5 minutes in the affected eye.

          6. Patients with severe blepharitis and/or severe meibomian gland disease in the affected
             eye.

          7. History of any ocular surgery (including laser or refractive surgical procedures) in
             the affected eye within the three months before study enrolment. (An exception to the
             preceding statement will be allowed if the ocular surgery is considered to be the
             cause of the stage 2 or 3 NK). Ocular surgery in the affected eye will not be allowed
             during the study treatment period and elective ocular surgery procedures should not be
             planned during the duration of the follow-up period.

          8. Prior surgical procedure(s) for the treatment of NK (e.g. complete tarsorraphy,
             conjunctival flap, etc) in the affected eye with the exception of amniotic membrane
             transplantation. Patients previously treated with amniotic membrane transplantation
             may only be enrolled two weeks after the membrane has disappeared within the area of
             the PED or corneal ulcer or at least six weeks after the date of the amniotic membrane
             transplantation procedure. Patients previously treated with Botox (botulinum toxin)
             injections used to induce pharmacologic blepharoptosis are eligible for enrolment only
             if the last injection was given at least 90 days prior to enrolment in the study.

          9. Use of therapeutic contact lenses or contact lens wear for refractive correction
             during the study treatment periods in the eye with NK.

         10. Anticipated need for punctual occlusion during the study treatment period. Patients
             with punctual occlusion or punctual plugs inserted prior to the study are eligible for
             enrolment provided that the punctual occlusion is maintained during the study.

         11. Evidence of corneal ulceration involving the posterior third of the corneal stroma,
             corneal melting or perforation in the affected eye.

         12. Presence or history of any ocular or systemic disorder or condition that might hinder
             the efficacy of the study treatment or its evaluation, could possibly interfere with
             the interpretation of study results, or could be judged by the investigator to be
             incompatible with the study visit schedule or conduct (e.g. progressive or
             degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly controlled
             diabetes, autoimmune disease, systemic infection, neoplastic diseases).

         13. Any need for or anticipated change in the dose of systemic medications known to impair
             the function of the trigeminal nerve (e.g. neuroleptics, antipsychotic and
             antihistamine drugs). These treatments are allowed during the study if initiated prior
             to 30 days before study enrolment provided they remain stable throughout the course of
             the study treatment periods.

         14. Known hypersensitivity to one of the components of the study or procedural medications
             (e.g. fluorescein).

         15. History of drug, medication or alcohol abuse or addiction.

         16. Use of any investigational agent within 4 weeks of screening visit.

         17. Participation in another clinical study at the same time as the present study.

         18. Females of childbearing potential (those who are not surgically sterilized or
             post-menopausal for at least 1 year) are excluded from participation in the study if
             they meet any one of the following conditions: are currently pregnant or have a
             positive result on the urine pregnancy test at the Randomization Visit or intend to
             become pregnant during the study treatment period or are breast-feeding or not willing
             to use highly effective birth control measures, such as: Hormonal contraceptives
             -oral, implanted, transdermal, or injected and/or Mechanical barrier methods
             -spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during
             the entire course of and 30 days after the study treatment periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Sinigaglia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dompé s.p.a., Milan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Dijon - Service ophtalmologie</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren - Service Ophtalmologie</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtalmologie - Service d'ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75 571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Fondation Ophtalmologique Adolphe de Rothschild - &quot;Unité de Recherche Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;CHU Toulouse-Purpan - Service Ophtalmologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic in Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln - Zentrum für Augenheilkunde am Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität Augenklinik und Poliklinik - Department of Ophthalmology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Augenklinik der Ludwig-Maximilians-Universtiät München</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSPEDALE SAN RAFFAELE di Milano</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università G. D' Annunzio - Clinica Oftalmologica - Centro regionale di Eccellenza in Oftalmologia</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Neurologiche Oftalmologia e Genetica - Universtità di Genova</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Messina - Dipartimento Specialità Chirurgiche Ambulatorio Studio delle Malattie dela Superficie Oculare Unità Operativa Complessa di Oftalmologia</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo - U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera di Padova - Clinica Oculistica Policlinico 7° Piano</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Railway Hospital Katowice - Department of Ophthalmology</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;SPKSO Szpital Okulistyczny ul. - SPKSO Szpital Okulistyczny</name>
      <address>
        <city>Warsawa</city>
        <zip>03-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vissum Corporación Oftalmológica de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces - Oftalmología</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barraquer Eye center</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona - Oftalmología</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos - Oftalmología. Unidad de Superficie Ocular</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Fernández-Vega - Oftalmología</name>
      <address>
        <city>Oviedo</city>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cartuja Visión - Oftalmología</name>
      <address>
        <city>Sevilla</city>
        <zip>41092</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham - Academic Unit of Ophthalmology, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>&quot;B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital - Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital - Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary - Dept. of Ophthalmology</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southampton Southampton General Hospital - MP104, Eye Unit</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <results_first_submitted>February 1, 2018</results_first_submitted>
  <results_first_submitted_qc>July 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2019</results_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratitis</keyword>
  <keyword>Corneal Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of 2 periods: 8week PhaseI/controlled treatment period and 48/56-week FU period. In the Phase1 patients were randomized into 2 cohorts (of 9 pts each). In phase 2 pts were randomized in a 1:1:1 ratio (52 pts each group). Data refer to the 1st database lock when the last patient in Phase2 had completed 12 weeks of FU period.</recruitment_details>
      <pre_assignment_details>The inclusion/exclusion criteria were designed to include individuals 18 years of age or older with Stage 2 (PED) or Stage 3 (corneal ulcer) NK involving only 1 eye and to exclude those with Stage 2 or 3 NK affecting both eyes, any active ocular infection or inflammation not related to NK, or any ocular disease or severe vision loss.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1_rhNGF 10µg/ml Phase 1_treatment</title>
          <description>rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="P2">
          <title>2_rhNGF 20 µg/ml_Phase 1_treatment</title>
          <description>rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="P3">
          <title>3_vehicle group_Phase 1_treatment</title>
          <description>Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="P4">
          <title>4_rhNGF10_Phase 2_treatment</title>
          <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
        </group>
        <group group_id="P5">
          <title>5_rhNGF20_Phase 2_treatment</title>
          <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
        </group>
        <group group_id="P6">
          <title>6_vehicle group_Phase 2_treatment</title>
          <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period: Phase I/II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>decision unrelated to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other causes</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow Up Period Phase I/II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>still in study after week 20</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>parent withdrew the consent to continue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other causes</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1_rhNGF10_Phase 1_treatment</title>
          <description>rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="B2">
          <title>2_rhNGF20_Phase 1_treatment</title>
          <description>rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="B3">
          <title>3_vehicle group_Phase 1_treatment</title>
          <description>Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="B4">
          <title>4_rhNGF10_Phase 2_treatment</title>
          <description>rhNGF 10 µg/ml eye drops solution: rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="B5">
          <title>5_rhNGF20_Phase 2_treatment</title>
          <description>rhNGF 20 µg/ml eye drops solution: rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="B6">
          <title>6_vehicle group_Phase 2_treatment</title>
          <description>Placebo: Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="52"/>
            <count group_id="B7" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The patients populations of Phase I and Phase II are different. The first consists of 18 individuals, the second of 156 individuals.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="21.47"/>
                    <measurement group_id="B2" value="52.0" spread="17.24"/>
                    <measurement group_id="B3" value="64.3" spread="24.06"/>
                    <measurement group_id="B4" value="59.0" spread="17.17"/>
                    <measurement group_id="B5" value="62.5" spread="14.01"/>
                    <measurement group_id="B6" value="60.4" spread="16.78"/>
                    <measurement group_id="B7" value="58.5" spread="19.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
        <description>Complete healing of the PED or corneal ulcer was determined by corneal fluorescein staining at 4 weeks as defined by the reading center evaluating the clinical pictures.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm at the Week 4 visit.
The primary efficacy variable was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
        <time_frame>at 4 weeks of treatment</time_frame>
        <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
          <description>Complete healing of the PED or corneal ulcer was determined by corneal fluorescein staining at 4 weeks as defined by the reading center evaluating the clinical pictures.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm at the Week 4 visit.
The primary efficacy variable was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
          <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Phase II</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Each of the comparisons was conducted on the data for the Phase II segment of the study using a 2 × 2 chi-square test, based on the null hypothesis that there is no association between treatment (rhNGF or Vehicle Control) and response (Complete Healing at Week 4 [Yes/No]).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>35.3</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.88</ci_lower_limit>
            <ci_upper_limit>54.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Each of the comparisons was conducted on the data for the Phase II segment of the study using a 2 × 2 chi-square test, based on the null hypothesis that there is no association between treatment (rhNGF or Vehicle Control) and response (Complete Healing at Week 4 [Yes/No]).</non_inferiority_desc>
            <p_value>=0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>38.4</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.96</ci_lower_limit>
            <ci_upper_limit>57.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
        <description>Complete healing of the PED or corneal ulcer at 4 weeks as defined by the Investigator. The complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer, being less than 0.5 mm at the Week 4 visit.
This secondary outcome was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
        <time_frame>at 4 weeks of study treatment.</time_frame>
        <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
          <description>Complete healing of the PED or corneal ulcer at 4 weeks as defined by the Investigator. The complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer, being less than 0.5 mm at the Week 4 visit.
This secondary outcome was analyzed after 4 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
          <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.016</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>25.8</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.66</ci_lower_limit>
            <ci_upper_limit>47.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.002</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>34.7</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.91</ci_lower_limit>
            <ci_upper_limit>57.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
        <description>Complete healing of the PED or corneal ulcer at 6 and 8 weeks measured by both the central reading center and Investigator.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm.
This outcome was analyzed after 6 and 8 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
        <time_frame>at 6 and 8 weeks after start of the treatment</time_frame>
        <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer</title>
          <description>Complete healing of the PED or corneal ulcer at 6 and 8 weeks measured by both the central reading center and Investigator.
Complete healing was defined as the greatest diameter of the corneal fluorescein staining in the area of the PED or corneal ulcer being less than 0.5 mm.
This outcome was analyzed after 6 and 8 weeks of treatment only for the Phase II segment of the study. That's why the Phase I groups/arms are not included in this analysis.</description>
          <population>Phase II patients who achieved complete healing at Week 4 (last observation carried forward - LOCF) as determined by the reading center (ITT population).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 6 - central reading center - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - central reading center - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - investigator - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - investigator - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - central reading center - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - central reading center - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - investigator - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - investigator - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At week 6 - reading center</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.818</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>2.4</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.30</ci_lower_limit>
            <ci_upper_limit>25.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>at week 6 - central reading center</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.571</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.62</ci_lower_limit>
            <ci_upper_limit>17.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 6 - investigator</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.064</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>20.3</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.11</ci_lower_limit>
            <ci_upper_limit>43.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 6 - investigator</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.041</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>23.1</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>47.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 8 - central reading center</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.031</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>21.9</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>43.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 8 - central reading center</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.008</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>26.9</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.57</ci_lower_limit>
            <ci_upper_limit>48.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 8 - investigator</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.011</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>26.1</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.18</ci_lower_limit>
            <ci_upper_limit>48.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 8 - investigator</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.014</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentage</param_type>
            <param_value>25.9</param_value>
            <ci_percent>97.06</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.55</ci_lower_limit>
            <ci_upper_limit>48.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing Complete Corneal Clearing</title>
        <description>Complete corneal clearing (grade 0 on the modified Oxford scale) at 4, 6 and 8 weeks.
A patient was considered to have achieved complete corneal clearing if he/she had a Modified Oxford Scale recorded as Grade 0.
The scale has the following grades: 0-1-2-3-4-5, where 5 represents the worst outcome value and 0 the best outcome value.</description>
        <time_frame>at 4, 6 and 8 weeks after start of the treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Complete Corneal Clearing</title>
          <description>Complete corneal clearing (grade 0 on the modified Oxford scale) at 4, 6 and 8 weeks.
A patient was considered to have achieved complete corneal clearing if he/she had a Modified Oxford Scale recorded as Grade 0.
The scale has the following grades: 0-1-2-3-4-5, where 5 represents the worst outcome value and 0 the best outcome value.</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 -yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.065</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>27.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.097</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.05</ci_lower_limit>
            <ci_upper_limit>26.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.036</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.97</ci_lower_limit>
            <ci_upper_limit>31.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.054</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>31.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.043</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>32.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.157</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.08</ci_lower_limit>
            <ci_upper_limit>26.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Best Corrected Distance Visual Acuity (BCDVA)</title>
        <description>Mean changes in Best-Corrected Distance Visual Acuity (BCDVA) from baseline to Week 8 are calculated as Least Square means. BCDVA consists of letters read at 4 meters only. Patients are scored by how many letters could be correctly identified. Therefore the higher the number of letters, the higher the visual acuity.</description>
        <time_frame>At screening and at week 8</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Distance Visual Acuity (BCDVA)</title>
          <description>Mean changes in Best-Corrected Distance Visual Acuity (BCDVA) from baseline to Week 8 are calculated as Least Square means. BCDVA consists of letters read at 4 meters only. Patients are scored by how many letters could be correctly identified. Therefore the higher the number of letters, the higher the visual acuity.</description>
          <population>ITT population</population>
          <units>LogMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="2.58"/>
                    <measurement group_id="O2" value="11.9" spread="2.80"/>
                    <measurement group_id="O3" value="6.9" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.022</p_value>
            <method>ANCOVA</method>
            <param_type>least square mean difference</param_type>
            <param_value>8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>16.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.213</p_value>
            <method>ANCOVA</method>
            <param_type>least square mean difference</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>12.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients That Achieve an Improvement in Corneal Sensitivity</title>
        <description>Percentage of patients that achieve an improvement in corneal sensitivity as measured by the Cochet-Bonnet aesthesiometer</description>
        <time_frame>at 4, 6 and 8 weeks.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients That Achieve an Improvement in Corneal Sensitivity</title>
          <description>Percentage of patients that achieve an improvement in corneal sensitivity as measured by the Cochet-Bonnet aesthesiometer</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 -yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.592</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.53</ci_lower_limit>
            <ci_upper_limit>25.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>week 4</non_inferiority_desc>
            <p_value>=0.835</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.01</ci_lower_limit>
            <ci_upper_limit>19.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.008</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>27.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.10</ci_lower_limit>
            <ci_upper_limit>47.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.282</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.91</ci_lower_limit>
            <ci_upper_limit>34.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.303</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>10.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.15</ci_lower_limit>
            <ci_upper_limit>29.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.442</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.13</ci_lower_limit>
            <ci_upper_limit>27.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing Deterioration in Stage 2 or 3 NK</title>
        <description>Percentage of patients experiencing deterioration (increase in lesion size ≥ 1mm, decrease in BCDVA by &gt;5 ETDRS letters, progression in lesion depth to corneal melting or perforation, onset of infection) in stage 2 or 3 NK from baseline to Week 4, 6, and 8.</description>
        <time_frame>from baseline to Week 4, 6, and 8.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Deterioration in Stage 2 or 3 NK</title>
          <description>Percentage of patients experiencing deterioration (increase in lesion size ≥ 1mm, decrease in BCDVA by &gt;5 ETDRS letters, progression in lesion depth to corneal melting or perforation, onset of infection) in stage 2 or 3 NK from baseline to Week 4, 6, and 8.</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 -yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.597</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.87</ci_lower_limit>
            <ci_upper_limit>17.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.26</ci_lower_limit>
            <ci_upper_limit>18.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.183</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.70</ci_lower_limit>
            <ci_upper_limit>13.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.116</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.41</ci_lower_limit>
            <ci_upper_limit>11.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.134</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.30</ci_lower_limit>
            <ci_upper_limit>10.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.307</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>-7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.51</ci_lower_limit>
            <ci_upper_limit>13.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Complete Healing of the PED or Corneal Ulcer by Week 8/16 That Remain Healed at Weeks 20/28, 32/40, 44/52, 56/64</title>
        <description>Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 that remain healed (ie, no recurrence of the PED and/or corneal ulcer) at Weeks 20/28, 32/40, 44/52, 56/64</description>
        <time_frame>at week 20/28, 32/40, 44/52, and 56/64</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Complete Healing of the PED or Corneal Ulcer by Week 8/16 That Remain Healed at Weeks 20/28, 32/40, 44/52, 56/64</title>
          <description>Percentage of patients achieving complete healing of the PED or corneal ulcer by Week 8/16 that remain healed (ie, no recurrence of the PED and/or corneal ulcer) at Weeks 20/28, 32/40, 44/52, 56/64</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 20/28 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="87"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20/28 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 32/40 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 32/40 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 44/52 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 44/52 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 56/64 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 56/64 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing a Different Level of Efficacy at 4 and 8 Weeks</title>
        <description>Global evaluation of efficacy as assessed by the Investigator at 4 and 8 weeks. The different level of efficacy were: very good; good; moderate; poor; non-evaluable.</description>
        <time_frame>at week 4 and 8</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing a Different Level of Efficacy at 4 and 8 Weeks</title>
          <description>Global evaluation of efficacy as assessed by the Investigator at 4 and 8 weeks. The different level of efficacy were: very good; good; moderate; poor; non-evaluable.</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 - very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - non-evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - non-evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.041</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>4.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.081</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.040</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>5.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.132</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>4.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Analogue Scale (VAS) for Ocular Tolerability</title>
        <description>Ocular tolerability was recorded by the patient on a VAS scale from 0 to 100 mm, where a higher VAS score indicates worse ocular symptoms (0 means no symptoms and 100 means the worst possible discomfort). The overall VAS score for ocular tolerability was calculated as the mean of the individual VAS scores for the 7 different symptoms (foreign body sensation, burning/stinging, itching, ocular pain, sticky feeling, blurred vision and photophobia).
Results are below reported as per symptoms at week 8 (for treatment period) and week 20 (for Follow Up period).</description>
        <time_frame>at baseline and at weeks 8 and 20</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O7">
            <title>1_rhNGF10_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O8">
            <title>2_rhNGF20_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O9">
            <title>3_vehicle group_Phase 1_FU</title>
            <description>Follow up for Phase 1 vehicle control arm</description>
          </group>
          <group group_id="O10">
            <title>4_rhNGF10_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O11">
            <title>5_rhNGF20_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O12">
            <title>6_vehicle_Phase 2_FU</title>
            <description>Follow up for Phase 2 vehicle control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Analogue Scale (VAS) for Ocular Tolerability</title>
          <description>Ocular tolerability was recorded by the patient on a VAS scale from 0 to 100 mm, where a higher VAS score indicates worse ocular symptoms (0 means no symptoms and 100 means the worst possible discomfort). The overall VAS score for ocular tolerability was calculated as the mean of the individual VAS scores for the 7 different symptoms (foreign body sensation, burning/stinging, itching, ocular pain, sticky feeling, blurred vision and photophobia).
Results are below reported as per symptoms at week 8 (for treatment period) and week 20 (for Follow Up period).</description>
          <population>Safety population</population>
          <units>VAS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="45"/>
                <count group_id="O11" value="39"/>
                <count group_id="O12" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Foreign Body Sensation_Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="25.68"/>
                    <measurement group_id="O2" value="24" spread="19.76"/>
                    <measurement group_id="O3" value="20.5" spread="29.23"/>
                    <measurement group_id="O4" value="34.8" spread="29.4"/>
                    <measurement group_id="O5" value="35.4" spread="34.79"/>
                    <measurement group_id="O6" value="37.7" spread="36.49"/>
                    <measurement group_id="O7" value="50.4" spread="25.68"/>
                    <measurement group_id="O8" value="24" spread="19.76"/>
                    <measurement group_id="O9" value="20.5" spread="29.23"/>
                    <measurement group_id="O10" value="34.8" spread="29.4"/>
                    <measurement group_id="O11" value="35.4" spread="34.79"/>
                    <measurement group_id="O12" value="37.7" spread="36.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Foreign Body Sensation_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="25.96"/>
                    <measurement group_id="O2" value="-12.9" spread="17.03"/>
                    <measurement group_id="O3" value="-16" spread="65.05"/>
                    <measurement group_id="O4" value="-8.8" spread="34.68"/>
                    <measurement group_id="O5" value="-16.5" spread="36.87"/>
                    <measurement group_id="O6" value="-20.9" spread="35.86"/>
                    <measurement group_id="O7" value="-20" spread="30.32"/>
                    <measurement group_id="O8" value="-13" spread="25.3"/>
                    <measurement group_id="O9" value="-52" spread="0"/>
                    <measurement group_id="O10" value="-16.6" spread="31.26"/>
                    <measurement group_id="O11" value="-22.4" spread="38.77"/>
                    <measurement group_id="O12" value="-20.7" spread="30.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>burning/stinging_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="30.85"/>
                    <measurement group_id="O2" value="30.7" spread="38.78"/>
                    <measurement group_id="O3" value="18" spread="28.57"/>
                    <measurement group_id="O4" value="32.5" spread="32.88"/>
                    <measurement group_id="O5" value="26.5" spread="30.86"/>
                    <measurement group_id="O6" value="30.2" spread="32.21"/>
                    <measurement group_id="O7" value="41.4" spread="30.85"/>
                    <measurement group_id="O8" value="30.7" spread="38.78"/>
                    <measurement group_id="O9" value="18" spread="28.57"/>
                    <measurement group_id="O10" value="32.5" spread="32.88"/>
                    <measurement group_id="O11" value="26.5" spread="30.86"/>
                    <measurement group_id="O12" value="30.2" spread="32.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>burning/stinging_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="38.02"/>
                    <measurement group_id="O2" value="-12.1" spread="28.27"/>
                    <measurement group_id="O3" value="-28.5" spread="23.33"/>
                    <measurement group_id="O4" value="-3.8" spread="42.13"/>
                    <measurement group_id="O5" value="-2.5" spread="26.76"/>
                    <measurement group_id="O6" value="-18" spread="32.97"/>
                    <measurement group_id="O7" value="-18" spread="41.65"/>
                    <measurement group_id="O8" value="-16.5" spread="17.13"/>
                    <measurement group_id="O9" value="-12" spread="0"/>
                    <measurement group_id="O10" value="-14.9" spread="40.35"/>
                    <measurement group_id="O11" value="-10.8" spread="31.51"/>
                    <measurement group_id="O12" value="-14.7" spread="37.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>itching_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="27.4"/>
                    <measurement group_id="O2" value="18.7" spread="19.62"/>
                    <measurement group_id="O3" value="7.8" spread="15.5"/>
                    <measurement group_id="O4" value="24.1" spread="27.48"/>
                    <measurement group_id="O5" value="21.8" spread="28.68"/>
                    <measurement group_id="O6" value="22.9" spread="28.43"/>
                    <measurement group_id="O7" value="17" spread="27.4"/>
                    <measurement group_id="O8" value="18.7" spread="19.62"/>
                    <measurement group_id="O9" value="7.8" spread="15.5"/>
                    <measurement group_id="O10" value="24.1" spread="27.48"/>
                    <measurement group_id="O11" value="21.8" spread="28.68"/>
                    <measurement group_id="O12" value="22.9" spread="28.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>itching_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="17.93"/>
                    <measurement group_id="O2" value="-10" spread="23.1"/>
                    <measurement group_id="O3" value="-15.5" spread="21.92"/>
                    <measurement group_id="O4" value="-10.8" spread="29.25"/>
                    <measurement group_id="O5" value="-7.3" spread="22.67"/>
                    <measurement group_id="O6" value="-8.9" spread="25.59"/>
                    <measurement group_id="O7" value="-7.8" spread="27.18"/>
                    <measurement group_id="O8" value="-4.2" spread="28.51"/>
                    <measurement group_id="O9" value="-31" spread="0"/>
                    <measurement group_id="O10" value="-10.2" spread="30.62"/>
                    <measurement group_id="O11" value="-11.9" spread="23.05"/>
                    <measurement group_id="O12" value="-4.8" spread="30.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ocular pain_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="36.96"/>
                    <measurement group_id="O2" value="33.6" spread="34.73"/>
                    <measurement group_id="O3" value="19" spread="38"/>
                    <measurement group_id="O4" value="32.8" spread="34.86"/>
                    <measurement group_id="O5" value="21.1" spread="28.38"/>
                    <measurement group_id="O6" value="28.8" spread="32.82"/>
                    <measurement group_id="O7" value="34.1" spread="36.96"/>
                    <measurement group_id="O8" value="33.6" spread="34.73"/>
                    <measurement group_id="O9" value="19" spread="38"/>
                    <measurement group_id="O10" value="32.8" spread="34.86"/>
                    <measurement group_id="O11" value="21.1" spread="28.38"/>
                    <measurement group_id="O12" value="28.8" spread="32.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ocular pain_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2" spread="28.96"/>
                    <measurement group_id="O2" value="-6" spread="30.72"/>
                    <measurement group_id="O3" value="-23" spread="32.53"/>
                    <measurement group_id="O4" value="-2" spread="43"/>
                    <measurement group_id="O5" value="2" spread="37.25"/>
                    <measurement group_id="O6" value="-16.3" spread="30.52"/>
                    <measurement group_id="O7" value="-16" spread="28.59"/>
                    <measurement group_id="O8" value="-9.3" spread="11.86"/>
                    <measurement group_id="O9" value="-26" spread="0"/>
                    <measurement group_id="O10" value="-16.7" spread="34.66"/>
                    <measurement group_id="O11" value="-12.1" spread="31.25"/>
                    <measurement group_id="O12" value="-18.3" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sticky feeling_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="34.14"/>
                    <measurement group_id="O2" value="32.1" spread="35.34"/>
                    <measurement group_id="O3" value="15.5" spread="23.69"/>
                    <measurement group_id="O4" value="26.6" spread="29.65"/>
                    <measurement group_id="O5" value="17.4" spread="22.07"/>
                    <measurement group_id="O6" value="26.1" spread="31.93"/>
                    <measurement group_id="O7" value="47.6" spread="34.14"/>
                    <measurement group_id="O8" value="32.1" spread="35.34"/>
                    <measurement group_id="O9" value="15.5" spread="23.69"/>
                    <measurement group_id="O10" value="26.6" spread="29.65"/>
                    <measurement group_id="O11" value="17.4" spread="22.07"/>
                    <measurement group_id="O12" value="26.1" spread="31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sticky feeling_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="42.82"/>
                    <measurement group_id="O2" value="-18.7" spread="38.32"/>
                    <measurement group_id="O3" value="-11" spread="5.66"/>
                    <measurement group_id="O4" value="-11.7" spread="30.17"/>
                    <measurement group_id="O5" value="-4.3" spread="29.55"/>
                    <measurement group_id="O6" value="-10.7" spread="29.95"/>
                    <measurement group_id="O7" value="-19.8" spread="22.18"/>
                    <measurement group_id="O8" value="-0.7" spread="12.52"/>
                    <measurement group_id="O9" value="-2" spread="0"/>
                    <measurement group_id="O10" value="-13.3" spread="30.75"/>
                    <measurement group_id="O11" value="-11.4" spread="31.11"/>
                    <measurement group_id="O12" value="-8.3" spread="30.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>blurred vision_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="38.37"/>
                    <measurement group_id="O2" value="85.7" spread="14.74"/>
                    <measurement group_id="O3" value="93.5" spread="7.9"/>
                    <measurement group_id="O4" value="80.2" spread="25.18"/>
                    <measurement group_id="O5" value="83.2" spread="24.45"/>
                    <measurement group_id="O6" value="78.5" spread="24.68"/>
                    <measurement group_id="O7" value="71" spread="38.37"/>
                    <measurement group_id="O8" value="85.7" spread="14.74"/>
                    <measurement group_id="O9" value="93.5" spread="7.9"/>
                    <measurement group_id="O10" value="80.2" spread="25.18"/>
                    <measurement group_id="O11" value="83.2" spread="24.45"/>
                    <measurement group_id="O12" value="78.5" spread="24.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>blurred vision_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" spread="34.37"/>
                    <measurement group_id="O2" value="-25" spread="32.15"/>
                    <measurement group_id="O3" value="-22" spread="31.11"/>
                    <measurement group_id="O4" value="-24.9" spread="35.33"/>
                    <measurement group_id="O5" value="-26.2" spread="31.58"/>
                    <measurement group_id="O6" value="-17.4" spread="28.55"/>
                    <measurement group_id="O7" value="-26.5" spread="31.18"/>
                    <measurement group_id="O8" value="-26.2" spread="17.93"/>
                    <measurement group_id="O9" value="-14" spread="0"/>
                    <measurement group_id="O10" value="-16.5" spread="38.42"/>
                    <measurement group_id="O11" value="-25.7" spread="34.41"/>
                    <measurement group_id="O12" value="-17.4" spread="27.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>photophobia_baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="42.9"/>
                    <measurement group_id="O2" value="66.6" spread="29.85"/>
                    <measurement group_id="O3" value="30.3" spread="26.21"/>
                    <measurement group_id="O4" value="64.3" spread="32.07"/>
                    <measurement group_id="O5" value="57.6" spread="36.1"/>
                    <measurement group_id="O6" value="65.2" spread="34.71"/>
                    <measurement group_id="O7" value="64.7" spread="42.9"/>
                    <measurement group_id="O8" value="66.6" spread="29.85"/>
                    <measurement group_id="O9" value="30.3" spread="26.21"/>
                    <measurement group_id="O10" value="64.3" spread="32.07"/>
                    <measurement group_id="O11" value="57.6" spread="36.1"/>
                    <measurement group_id="O12" value="65.2" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>photophobia_CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.5" spread="27.98"/>
                    <measurement group_id="O2" value="-20.7" spread="34.13"/>
                    <measurement group_id="O3" value="-30.5" spread="43.13"/>
                    <measurement group_id="O4" value="-17.8" spread="41.23"/>
                    <measurement group_id="O5" value="-13.2" spread="40.44"/>
                    <measurement group_id="O6" value="-17.5" spread="29.02"/>
                    <measurement group_id="O7" value="-20.3" spread="28.63"/>
                    <measurement group_id="O8" value="-26" spread="39.88"/>
                    <measurement group_id="O9" value="-61" spread="0"/>
                    <measurement group_id="O10" value="-24.2" spread="37.51"/>
                    <measurement group_id="O11" value="-21" spread="38.76"/>
                    <measurement group_id="O12" value="-14.6" spread="29.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)</title>
        <description>Best-Corrected Distance Visual Acuity (BCDVA) by means of the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart at 4 meters (13 feet). Data reported refers to week n° 8 (treatment group) and n°12/20 (FU group).</description>
        <time_frame>at baseline and at period 1 (8 weeks) and 2 (Follow Up period of 12 weeks, until week 20)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O7">
            <title>1_rhNGF10_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O8">
            <title>2_rhNGF20_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O9">
            <title>3_vehicle group_Phase 1_FU</title>
            <description>Follow up for Phase 1 vehicle control arm</description>
          </group>
          <group group_id="O10">
            <title>4_rhNGF10_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O11">
            <title>5_rhNGF20_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O12">
            <title>6_vehicle_Phase 2_FU</title>
            <description>Follow up for Phase 2 vehicle control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)</title>
          <description>Best-Corrected Distance Visual Acuity (BCDVA) by means of the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart at 4 meters (13 feet). Data reported refers to week n° 8 (treatment group) and n°12/20 (FU group).</description>
          <population>Safety population</population>
          <units>Number of ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="45"/>
                <count group_id="O11" value="39"/>
                <count group_id="O12" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="28.25"/>
                    <measurement group_id="O2" value="30.4" spread="24.85"/>
                    <measurement group_id="O3" value="9.5" spread="11.96"/>
                    <measurement group_id="O4" value="30.7" spread="28.35"/>
                    <measurement group_id="O5" value="24.2" spread="25.88"/>
                    <measurement group_id="O6" value="32.4" spread="26.07"/>
                    <measurement group_id="O7" value="42" spread="28.25"/>
                    <measurement group_id="O8" value="30.4" spread="24.85"/>
                    <measurement group_id="O9" value="9.5" spread="11.96"/>
                    <measurement group_id="O10" value="30.7" spread="28.35"/>
                    <measurement group_id="O11" value="24.2" spread="25.88"/>
                    <measurement group_id="O12" value="32.4" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="5.89"/>
                    <measurement group_id="O2" value="8.7" spread="12.41"/>
                    <measurement group_id="O3" value="-1" spread="1.41"/>
                    <measurement group_id="O4" value="15.8" spread="16.82"/>
                    <measurement group_id="O5" value="11.9" spread="20.9"/>
                    <measurement group_id="O6" value="6.9" spread="15.44"/>
                    <measurement group_id="O7" value="11.2" spread="7.47"/>
                    <measurement group_id="O8" value="7" spread="9.8"/>
                    <measurement group_id="O9" value="-6" spread="0"/>
                    <measurement group_id="O10" value="13.2" spread="16.8"/>
                    <measurement group_id="O11" value="14.2" spread="19.6"/>
                    <measurement group_id="O12" value="8.8" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intraocular Pressure (IOP)</title>
        <description>IOP was measured using a Goldmann applanation tonometer, a handheld applanation tonometer [eg, Tonopen], or other tonometer, after the instillation of a topical anesthetic.</description>
        <time_frame>Baseline, period 1 (8 weeks) and 2 (Follow Up period of 12 weeks, until week 20).</time_frame>
        <population>safety population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O7">
            <title>1_rhNGF10_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O8">
            <title>2_rhNGF20_Phase 1_FU</title>
            <description>Follow up for Phase 1 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O9">
            <title>3_vehicle group_Phase 1_FU</title>
            <description>Follow up for Phase 1 vehicle control arm</description>
          </group>
          <group group_id="O10">
            <title>4_rhNGF10_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 10 μg/ml</description>
          </group>
          <group group_id="O11">
            <title>5_rhNGF20_Phase 2_FU</title>
            <description>Follow up for Phase 2 active treatment with rhNGF 20 μg/ml</description>
          </group>
          <group group_id="O12">
            <title>6_vehicle_Phase 2_FU</title>
            <description>Follow up for Phase 2 vehicle control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intraocular Pressure (IOP)</title>
          <description>IOP was measured using a Goldmann applanation tonometer, a handheld applanation tonometer [eg, Tonopen], or other tonometer, after the instillation of a topical anesthetic.</description>
          <population>safety population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="45"/>
                <count group_id="O11" value="39"/>
                <count group_id="O12" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="3.85"/>
                    <measurement group_id="O2" value="11.3" spread="3.68"/>
                    <measurement group_id="O3" value="11.8" spread="3.3"/>
                    <measurement group_id="O4" value="14.3" spread="3.16"/>
                    <measurement group_id="O5" value="14" spread="3.06"/>
                    <measurement group_id="O6" value="14.1" spread="3.16"/>
                    <measurement group_id="O7" value="16.1" spread="3.85"/>
                    <measurement group_id="O8" value="11.3" spread="3.68"/>
                    <measurement group_id="O9" value="11.8" spread="3.3"/>
                    <measurement group_id="O10" value="14.3" spread="3.16"/>
                    <measurement group_id="O11" value="14" spread="3.06"/>
                    <measurement group_id="O12" value="14.1" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.48"/>
                    <measurement group_id="O2" value="1.9" spread="5.24"/>
                    <measurement group_id="O3" value="3.5" spread="2.12"/>
                    <measurement group_id="O4" value="-0.1" spread="3.71"/>
                    <measurement group_id="O5" value="0.9" spread="2.61"/>
                    <measurement group_id="O6" value="0.8" spread="3.43"/>
                    <measurement group_id="O7" value="-2.2" spread="2.49"/>
                    <measurement group_id="O8" value="2.3" spread="3.78"/>
                    <measurement group_id="O9" value="-3" spread="0"/>
                    <measurement group_id="O10" value="0.2" spread="3.25"/>
                    <measurement group_id="O11" value="0.1" spread="3.64"/>
                    <measurement group_id="O12" value="0.6" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal Eye Structures by Dilated Fundus Ophthalmoscopy</title>
        <description>Dilated fundus ophthalmoscopy was performed to assess the vitreous, retina, macula, choroid and optic nerve head after dilation of the pupil.
Percentage of patients is summarized for each eye structure by treatment and visit for the controlled treatment period for Phase I and Phase II separately.
The assessment time points were Baseline, weeks 2, 4 and 8 for Phase 1; Baseline and week 8 for Phase 2; and weeks 12 and 56 for follow up.
Only results for eye structure at week 8 are reported.</description>
        <time_frame>At week 8 (Phase 1 and Phase 2)</time_frame>
        <population>safety population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Eye Structures by Dilated Fundus Ophthalmoscopy</title>
          <description>Dilated fundus ophthalmoscopy was performed to assess the vitreous, retina, macula, choroid and optic nerve head after dilation of the pupil.
Percentage of patients is summarized for each eye structure by treatment and visit for the controlled treatment period for Phase I and Phase II separately.
The assessment time points were Baseline, weeks 2, 4 and 8 for Phase 1; Baseline and week 8 for Phase 2; and weeks 12 and 56 for follow up.
Only results for eye structure at week 8 are reported.</description>
          <population>safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vitreous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="14.7"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retina macula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="17.6"/>
                    <measurement group_id="O5" value="23.3"/>
                    <measurement group_id="O6" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.8"/>
                    <measurement group_id="O5" value="6.5"/>
                    <measurement group_id="O6" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optic nerve</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="11.8"/>
                    <measurement group_id="O5" value="12.5"/>
                    <measurement group_id="O6" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Patients That Achieved a ≥15 Letter Gain in BCDVA</title>
        <description>Percentage of patients that achieved a ≥15 letter gain in best corrected distance visual acuity (BCDVA) at 4, 6, and 8 weeks</description>
        <time_frame>at 4, 6 and 8 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>1_rhNGF10_Phase 1_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O2">
            <title>2_rhNGF20_Phase 1_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O3">
            <title>3_vehicle group_Phase 1_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
          <group group_id="O4">
            <title>4_rhNGF10_Phase 2_treatment</title>
            <description>active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
rhNGF 10 μg/ml: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)</description>
          </group>
          <group group_id="O5">
            <title>5_rhNGF20_Phase 2_treatment</title>
            <description>active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
rhNGF 20 μg/ml: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)</description>
          </group>
          <group group_id="O6">
            <title>6_vehicle group_Phase 2_treatment</title>
            <description>vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
vehicle: ophthalmic solution of the same composition as the test product without rhNGF</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients That Achieved a ≥15 Letter Gain in BCDVA</title>
          <description>Percentage of patients that achieved a ≥15 letter gain in best corrected distance visual acuity (BCDVA) at 4, 6, and 8 weeks</description>
          <population>ITT population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 -yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 - no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.097</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>15.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>33.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.175</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.72</ci_lower_limit>
            <ci_upper_limit>32.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.105</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.11</ci_lower_limit>
            <ci_upper_limit>37.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.300</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.64</ci_lower_limit>
            <ci_upper_limit>31.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.008</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>27.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.33</ci_lower_limit>
            <ci_upper_limit>46.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.068</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentage</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>38.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at each time point of Phase I and Phase II of the study. Phase I: Days 1, 2, Weeks 1, 2, 3, 4, 6, Day 55, Week 8 Phase II: Weeks 1, 2, 3, 4, 6, 8</time_frame>
      <desc>The definition of adverse event and/or serious adverse event used to collect adverse event information does not differ from the clinicaltrials.gov Definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>1_rhNGF10_Phase 1</title>
          <description>rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="E2">
          <title>2_rhNGF20_Phase 1</title>
          <description>rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="E3">
          <title>3_vehicle group_Phase 1</title>
          <description>Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="E4">
          <title>4_rhNGF10_Phase 2_treatment</title>
          <description>rhNGF 10 µg/ml eye drops solution: rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="E5">
          <title>5_rhNGF20_Phase 2_treatment</title>
          <description>rhNGF 20 µg/ml eye drops solution: rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only</description>
        </group>
        <group group_id="E6">
          <title>6_vehicle group_Phase 2_treatment</title>
          <description>Placebo: Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal endotheliitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal opacity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neurotrophic keratopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal graft rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eyelid margin crusting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ocular hyperemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lacrimation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal deposits</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal endotheliitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal opacity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lagophthalmos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lenticular opacities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meibomianitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pseudopterygium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neurotrophic keratopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Instillation site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal graft rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blister infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes simplex ophtalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophtalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vital dye staining cornea present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Flavio Mantelli, MD, PhD</name_or_title>
      <organization>Dompè</organization>
      <phone>+3902583831</phone>
      <email>info@dompe.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

